CN108434239A - 补气血抗疲劳口服液及其制备方法 - Google Patents
补气血抗疲劳口服液及其制备方法 Download PDFInfo
- Publication number
- CN108434239A CN108434239A CN201810593921.1A CN201810593921A CN108434239A CN 108434239 A CN108434239 A CN 108434239A CN 201810593921 A CN201810593921 A CN 201810593921A CN 108434239 A CN108434239 A CN 108434239A
- Authority
- CN
- China
- Prior art keywords
- blood
- radix
- fruit
- oral liquid
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 117
- 210000004369 blood Anatomy 0.000 title claims abstract description 116
- 239000007788 liquid Substances 0.000 title claims abstract description 72
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 61
- 239000009636 Huang Qi Substances 0.000 claims abstract description 33
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 32
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 32
- 241000405414 Rehmannia Species 0.000 claims abstract description 30
- 240000006766 Cornus mas Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 127
- 235000019441 ethanol Nutrition 0.000 claims description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 238000003756 stirring Methods 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 33
- 238000004064 recycling Methods 0.000 claims description 21
- 238000001556 precipitation Methods 0.000 claims description 20
- 241000756943 Codonopsis Species 0.000 claims description 19
- 244000197580 Poria cocos Species 0.000 claims description 19
- 235000008599 Poria cocos Nutrition 0.000 claims description 19
- 238000005057 refrigeration Methods 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 17
- 244000020518 Carthamus tinctorius Species 0.000 claims description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 16
- 240000008397 Ganoderma lucidum Species 0.000 claims description 16
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 16
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 15
- 235000008434 ginseng Nutrition 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 241000005787 Cistanche Species 0.000 claims description 14
- 241000026010 Dendrobium candidum Species 0.000 claims description 14
- 210000003056 antler Anatomy 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 14
- 235000010234 sodium benzoate Nutrition 0.000 claims description 14
- 239000004299 sodium benzoate Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 241000432767 Asparagus setaceus Species 0.000 claims description 2
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 15
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 7
- 210000003995 blood forming stem cell Anatomy 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 3
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 64
- 210000000265 leukocyte Anatomy 0.000 description 45
- 102000001554 Hemoglobins Human genes 0.000 description 44
- 108010054147 Hemoglobins Proteins 0.000 description 44
- 238000002512 chemotherapy Methods 0.000 description 28
- 241000209020 Cornus Species 0.000 description 27
- 238000011282 treatment Methods 0.000 description 26
- 239000012141 concentrate Substances 0.000 description 18
- 241000432824 Asparagus densiflorus Species 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241001247821 Ziziphus Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000004820 blood count Methods 0.000 description 15
- 241000208340 Araliaceae Species 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 208000007502 anemia Diseases 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 11
- 208000002173 dizziness Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 8
- UICBCXONCUFSOI-UHFFFAOYSA-N n'-phenylacetohydrazide Chemical compound CC(=O)NNC1=CC=CC=C1 UICBCXONCUFSOI-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 229940100688 oral solution Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 5
- 210000003013 erythroid precursor cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000011132 hemopoiesis Effects 0.000 description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 240000008574 Capsicum frutescens Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 244000296102 Selinum monnieri Species 0.000 description 3
- 235000019084 Selinum monnieri Nutrition 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 208000006278 hypochromic anemia Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000011645 metastatic carcinoma Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 240000001659 Oldenlandia diffusa Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940019204 ferrous sulfate 50 mg Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- UIMIQJVANYZMKL-UHFFFAOYSA-N n-phenylacetohydrazide Chemical group CC(=O)N(N)C1=CC=CC=C1 UIMIQJVANYZMKL-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属中药制剂领域,尤其涉及一种补气血抗疲劳口服液及其制备方法,以重量份计,包括如下组分:黄芪120~400;熟地黄80~240;白芍50~150;山萸肉80~200;当归80~200;女贞子100~300。本发明具有生血、补血、健脾、益气之功效,同时对人体免疫力具有一定增强作用,能有效提高癌症病人的生活质量,加快多能造血干细胞、骨髓红系造血祖细胞的增殖、分化,进而促使血细胞等含量升高,恢复血象平衡,减轻癌症病人的疾病痛苦。
Description
技术领域
本发明属中药制剂领域,尤其涉及一种可加快多能造血干细胞、骨髓红系造血祖细胞增殖、分化,进而促使血细胞等含量升高,恢复血象平衡的补气血抗疲劳口服液及其制备方法。
背景技术
祖国医学认为,肿瘤的形成是由于人体“正气不足”所导致的。即先由人体的正气虚衰、脏腑功能失调,使气血痰湿积聚,邪毒乘虚而入,内外因相结合而形成癌瘤。基于以上对肿瘤发病机理的认识,癌症患者以正虚邪实症候为多见。而且在肿瘤到达晚期,或者通过手术、化疗、放疗等攻伐疗法之后,往往使机体内部造成严重的消耗和损伤,阴、阳、气、血虚衰等征象更为突出。其中,尤以造血系统为明显:肿瘤病人在治疗过程中,骨髓造血机能受到抑制,往往出现白细胞、血小板和红细胞下降,进而导致感染、出血和贫血的发生,使病情进一步恶化。根据“虚者补之”,“损者益之”的原则,扶正补益类药在治疗肿瘤过程中就具有重要的战略地位。
从中医理论来讲,脾胃为后天之本,气血生化之源。血液的生成主要是脾脏吸收水谷之精微化为营气,经过肺气作用注于心脉成为血液。而肾为先天之本,肾藏精,主骨生髓。髓充则能生血,髓虚则精血不能复生,肾精的封藏也必须要靠脾胃之气的不断补充。因此脾肾与现代医学的造血功能有密切关系。化疗药物可损害先天之本——“肾”和后天之本——“脾”,从而出现胃肠和造血功能障碍。
在脾胃正常完成消谷、布谷的同时,营养全身的任务也要靠其它脏腑阳气的补充及鼓舞。从生理功能上讲,中焦水谷精气上输到肺后,贯全身血脉要靠心阳的推动,化赤为血要靠心阳的温化。无心阳之作用,脾胃之气停运。因此,养生、益髓、生血必须补心肾之阳,益气、健脾方可治标固本。必须通过补心肾填精、生精益髓、益气健脾、养阴生津、温肾壮阳等不同功能特色的中药组合作用于机体,才能快速达到生血、补血的目的。反观现有的补益气血类中药配方,组方相对简单,成分单一,因此临床治疗效果欠佳,疗效不明显。
发明内容
本发明旨在克服现有技术的不足之处而提供一种具有生血、补血、健脾、益气之功效,同时对人体免疫力具有一定增强作用,能有效提高癌症病人的生活质量,加快多能造血干细胞和骨髓红系造血祖细胞增殖、分化,进而促使血细胞等含量升高,恢复血象平衡,减轻癌症病人疾病痛苦的补气血抗疲劳口服液及其制备方法。
为解决上述技术问题,本发明是这样实现的:
一种补气血抗疲劳口服液,以重量份计,包括如下组分:黄芪120~400;熟地黄80~240;白芍50~150;山萸肉80~200;当归80~200;女贞子100~300。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)将黄芪、熟地黄、白芍、山萸肉、当归及女贞子加水煎煮2~3次,再合并煎液,滤过,滤液浓缩至相对密度为1.10~1.20,75℃~85℃热测,后冷却至30℃~40℃;以重量份计,包括如下组分:黄芪120~400;熟地黄80~240;白芍50~150;山萸肉80~200;当归80~200;女贞子100~300;
(2)将步骤(1)所得产物加乙醇使含醇量达60%~85%,边加边搅拌使沉淀;再静置冷藏,滤过;
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.10~1.20的清膏;60℃热测;
(4)加纯化水调整药液总量,加入重量百分含量为0.1%~0.25%的苯甲酸钠,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
作为一种优选方案,本发明以重量份计,还含有如下组分:大枣40~120;天冬60~180;党参60~180;灵芝40~120;丹参60~120;甘草20~60;人参20~80;鹿茸片20~80;巴戟天40~120;川芎20~80;红花40~120;铁皮石斛60~150;仙茅20~60;肉苁蓉40~120;蛇床子40~120;茯苓40~120。
中医认为:气为血之帅,血为气之母;气行则血行,气滞则血瘀,因此欲补血必先补气。黄芪是中药补气药中最为常用且功效显著的药物,能治疗因气虚乏力、中气下陷引起的多种病症,又有敛汗固脱、托疮生肌、利水消肿之功效。当归有补血养血之功,为补血第一药,也具有调经止痛和润肠通便的功效。适用于心肝血虚证所致的面色苍白或萎黄、倦怠乏力、唇甲浅淡无华、头晕目眩、心悸失眠等症。黄芪与当归配伍,可益气养血,对血虚证有较好的治疗效果。熟地黄可养血滋阴,补精益髓,用于血虚萎黄、眩晕、心悸、失眠、月经不调、崩漏及肾阴不足,潮热、盗汗、遗精、消渴等证。山萸肉微温而不热,是一味平补阴阳的药品,不论阴虚或阳虚,都可配用。它具有补益肝肾、涩精固脱、收敛止汗、生津止渴的功效。女贞子为养阴常用药,可滋补肝肾、明目乌发,用于眩晕耳鸣、须发早白、目暗不明。白芍可平肝止痛,养血调经,敛阴止汗,用于自汗盗汗、头痛眩晕、血虚萎黄、月经不调等症。
本发明属于一种促进人体造血功能,使骨髓造血干细胞明显增加和红、白细胞快速生长,防治骨髓抑制的中药口服液,具有显著的升白扶正和增强免疫功能的作用。主要应用于因化疗、放疗所致的白细胞减少症,预防和治疗均有特效。亦用于防治其他原因引起的贫血、再生障碍性贫血、术后失血、腰膝酸软、神疲乏力、久病虚弱等症,是一种兼具治疗与保健双重功能的中药制剂。
本发明对造血系统作用比较全面:有加快多能造血干细胞、骨髓红系造血祖细胞增殖、分化的作用,进而促使血细胞等含量升高,恢复血象平衡,同时巨噬细胞和白细胞的吞噬能力也得到明显提升。癌症患者化疗前连续一周口服,可使患者增强自身机体对化疗药物的耐受性进而顺利完成化疗疗程;化疗后服用本品又能拮抗环磷酰胺等药物所致的骨髓抑制现象,因此也可用于改善化疗药物对人体免疫功能的抑制作用。
具体实施方式
下面结合具体实施例对本发明作进一步说明。本发明的保护范围不仅局限于下列内容的表述。
实施例1
补气血抗疲劳口服液,具体包括如下组分:黄芪250g、当归150g、熟地黄150g、山萸肉150g、白芍150g、女贞子100g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪250g、当归150g、熟地黄150g、山萸肉150g、白芍150g、女贞子100g。将以上6味药合并煎煮2次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时。
(2)将两次提取液合并,滤过,滤液浓缩至相对密度为1.10(85℃热测),后冷却至30℃。将浓缩液加乙醇使含醇量达70%,边加边搅拌使沉淀,在8℃的温度下静置冷藏48小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.10的清膏(60℃热测),加纯化水稀释药液体积至480ml。加入苯甲酸钠0.8g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例2
补气血抗疲劳口服液,具体包括如下组分:熟地黄240g、山萸肉200g、女贞子200g、黄芪120g、白芍100g、当归80g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)熟地黄240g、山萸肉200g、女贞子200g、黄芪120g、白芍100g、当归80g。将以上6味药合并煎煮2次:第一次加水8倍量,第二次加水6倍量,每次均煎煮2小时。
(2)将两次提取液合并,滤过,滤液浓缩至相对密度为1.15(80℃热测),后冷却至35℃。将浓缩液加乙醇使含醇量达75%,边加边搅拌使沉淀,在6℃的温度下静置冷藏36小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.15的清膏(60℃热测),加纯化水稀释药液体积至480ml。加入苯甲酸钠1g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例3
补气血抗疲劳口服液,具体包括如下组分:黄芪400g、女贞子300g、当归200g、熟地黄80g、山萸肉80g、白芍50g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪400g、女贞子300g、当归200g、熟地黄80g、山萸肉80g、白芍50g。将以上6味药合并煎煮3次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时;第三次加水4倍量,煎煮1小时。
(2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.20(75℃热测),后冷却至40℃。将浓缩液加乙醇使含醇量达80%,边加边搅拌使沉淀,在4℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.20的清膏(60℃热测),加纯化水稀释药液体积至560ml。加入苯甲酸钠1g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例4
补气血抗疲劳口服液,具体包括如下组分:黄芪300g、女贞子250g、熟地黄200g、天冬150g、山萸肉150g、白芍120g、当归100g、茯苓100g、党参100g、丹参100g、巴戟天80g、大枣70g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪300g、女贞子250g、熟地黄200g、天冬150g、山萸肉150g、白芍120g、当归100g、茯苓100g、党参100g、丹参100g、巴戟天80g、大枣70g。将以上12味药合并煎煮2次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时。
(2)将两次提取液合并,滤过,滤液浓缩至相对密度为1.12(85℃热测),后冷却至30℃。将浓缩液加乙醇使含醇量达75%,边加边搅拌使沉淀,在7℃的温度下静置冷藏48小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.12的清膏(60℃热测),加纯化水稀释药液体积至800ml。加入苯甲酸钠1.2g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例5
补气血抗疲劳口服液,具体包括如下组分:黄芪300g、女贞子250g、熟地黄200g、当归175g、铁皮石斛150g、党参150g、天冬150g、山萸肉150g、白芍100g、茯苓100g、灵芝100g、甘草50g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪300g、女贞子250g、熟地黄200g、当归175g、铁皮石斛150g、党参150g、天冬150g、山萸肉150g、白芍100g、茯苓100g、灵芝100g、甘草50g。将以上12味药合并煎煮2次:第一次加水8倍量,第二次加水6倍量,每次均煎煮2小时。
(2)将两次提取液合并,滤过,滤液浓缩至相对密度为1.16(80℃热测),后冷却至35℃。将浓缩液加乙醇使含醇量达65%,边加边搅拌使沉淀,在5℃的温度下静置冷藏30小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.19的清膏(60℃热测),加纯化水稀释药液体积至900ml。加入苯甲酸钠1.5g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例6
补气血抗疲劳口服液,具体包括如下组分:黄芪260g、熟地黄160g、党参150g、女贞子150g、山萸肉120g、当归120g、巴戟天120g、肉苁蓉120g、白芍120g、天冬100g、大枣100g、茯苓60g、川芎60g、红花40g、甘草20g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪260g、熟地黄160g、党参150g、女贞子150g、山萸肉120g、当归120g、巴戟天120g、肉苁蓉120g、白芍120g、天冬100g、大枣100g、茯苓60g、川芎60g、红花40g、甘草20g。将以上15味药合并煎煮3次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时;第三次加水4倍量,煎煮1小时。
(2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.15(80℃热测),后冷却至35℃。将浓缩液加乙醇使含醇量达80%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.15的清膏(60℃热测),加纯化水稀释药液体积至800ml。加入苯甲酸钠1.2g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例7
补气血抗疲劳口服液,具体包括如下组分:熟地黄240g、黄芪200g、女贞子200g、党参180g、山萸肉160g、当归120g、天冬120g、红花120g、蛇床子120g、大枣100g、白芍100g、茯苓80g、灵芝80g、川芎80g、铁皮石斛60g、人参50g、鹿茸片50g、甘草40g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)熟地黄240g、黄芪200g、女贞子200g、党参180g、山萸肉160g、当归120g、天冬120g、红花120g、蛇床子120g、大枣100g、白芍100g、茯苓80g、灵芝80g、川芎80g、铁皮石斛60g、人参50g、鹿茸片50g、甘草40g。将以上18味药合并煎煮3次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时;第三次加水4倍量,煎煮1小时。
(2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.13(85℃热测),后冷却至30℃。将浓缩液加乙醇使含醇量达60%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,浓缩液再次加入乙醇使含醇量达80%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(4)回收乙醇至无醇味,减压浓缩至相对密度为1.13的清膏(60℃热测),加纯化水稀释药液体积至1000ml。加入苯甲酸钠2g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例8
补气血抗疲劳口服液,具体包括如下组分:黄芪400g、当归200g、天冬180g、铁皮石斛150g、白芍150g、灵芝120g、丹参120g、肉苁蓉120g、女贞子100g、熟地黄80g、山萸肉80g、人参80g、鹿茸片80g、仙茅60g、党参60g、甘草60g、茯苓40g、大枣40g、红花40g、蛇床子40g、巴戟天40g、川芎20g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪400g、当归200g、天冬180g、铁皮石斛150g、白芍150g、灵芝120g、丹参120g、肉苁蓉120g、女贞子100g、熟地黄80g、山萸肉80g、人参80g、鹿茸片80g、仙茅60g、党参60g、甘草60g、茯苓40g、大枣40g、红花40g、蛇床子40g、巴戟天40g、川芎20g。将以上22味药合并煎煮3次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时;第三次加水4倍量,煎煮1小时。
(2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.20(75℃热测),后冷却至40℃。将浓缩液加乙醇使含醇量达60%,边加边搅拌使沉淀,在4℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,浓缩液再次加入乙醇使含醇量达85%,边加边搅拌使沉淀,在4℃的温度下静置冷藏24小时,滤过。
(4)回收乙醇至无醇味,减压浓缩至相对密度为1.18的清膏(60℃热测),加纯化水稀释药液体积至1200ml。加入苯甲酸钠2g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例9
补气血抗疲劳口服液,具体包括如下组分:黄芪400g、当归200g、天冬180g、白芍150g、灵芝120g、丹参120g、女贞子100g、熟地黄80g、山萸肉80g、仙茅60g、党参60g、甘草60g、茯苓40g、大枣40g、红花40g、蛇床子40g、巴戟天40g、川芎20g、铁皮石斛150g、肉苁蓉120g、人参80g、鹿茸片80g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)将中药饮片分为两组提取,应同时进行:
第一组:黄芪400g、当归200g、天冬180g、白芍150g、灵芝120g、丹参120g、女贞子100g、熟地黄80g、山萸肉80g、仙茅60g、党参60g、甘草60g、茯苓40g、大枣40g、红花40g、蛇床子40g、巴戟天40g、川芎20g。将以上18味药合并煎煮2次:第一次加水8倍量,第二次加水6倍量,每次均煎煮2小时。将两次提取液合并,滤过,滤液浓缩至相对密度为1.13(85℃热测),后冷却至30℃备用。
第二组:铁皮石斛150g、肉苁蓉120g、人参80g、鹿茸片80g。将以上4味药合并煎煮3次:每次均加水5倍量,第一次煎煮2小时,第二次煎煮1.5小时,第三次煎煮1小时。将三次提取液合并,滤过,滤液浓缩至相对密度为1.13(85℃热测),后冷却至30℃备用。
(2)将第一组和第二组中的提取液合并,加乙醇使含醇量达60%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,浓缩液再次加入乙醇使含醇量达85%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(4)回收乙醇至无醇味,减压浓缩至相对密度为1.18的清膏(60℃热测),加纯化水稀释药液体积至1200ml。加入苯甲酸钠2.3g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例10
补气血抗疲劳口服液,具体包括如下组分:黄芪400g、当归200g、天冬180g、白芍150g、灵芝120g、丹参120g、女贞子100g、熟地黄80g、山萸肉80g、仙茅60g、党参60g、甘草60g、茯苓40g、大枣40g、红花40g、蛇床子40g、巴戟天40g、川芎20g、铁皮石斛150g、肉苁蓉120g、人参80g、鹿茸片80g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
1.第一组:
(1.1)黄芪400g、当归200g、天冬180g、白芍150g、灵芝120g、丹参120g、女贞子100g、熟地黄80g、山萸肉80g、仙茅60g、党参60g、甘草60g、茯苓40g、大枣40g、红花40g、蛇床子40g、巴戟天40g、川芎20g。将以上18味药合并煎煮2次:第一次加水8倍量,第二次加水6倍量,每次均煎煮2小时。
(1.2)将两次提取液合并,滤过,滤液浓缩至相对密度为1.16(80℃热测),后冷却至35℃。将浓缩液加乙醇使含醇量达80%,边加边搅拌使沉淀,在8℃的温度下静置冷藏60小时,滤过。
(1.3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.20的清膏(60℃热测),加纯化水稀释药液体积至950ml。
2.第二组:
(2.1)铁皮石斛150g、肉苁蓉120g、人参80g、鹿茸片80g。将以上4味药合并煎煮3次:每次均加水5倍量,第一次煎煮2小时,第二次煎煮1.5小时,第三次煎煮1小时。
(2.2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.16(80℃热测),后冷却至35℃。将浓缩液加乙醇使含醇量达65%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(2.3)收取上层清液,回收乙醇至无醇味,浓缩液再次加入乙醇使含醇量达85%,边加边搅拌使沉淀,在5℃的温度下静置冷藏24小时,滤过。
(2.4)回收乙醇至无醇味,减压浓缩至相对密度为1.18的清膏(60℃热测),加纯化水稀释药液体积至250ml。
3.合并药液:
将(1.3)中的药液与(2.4)中的药液合并成1200ml,加入苯甲酸钠2.5g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例11
补气血抗疲劳口服液,具体包括如下组分:女贞子300g、熟地黄240g、山萸肉200g、黄芪120g、党参120g、巴戟天120g、蛇床子120g、茯苓120g、大枣120g、红花120g、铁皮石斛100g、白芍100g、当归80g、川芎80g、天冬60g、丹参60g、灵芝40g、肉苁蓉40g、甘草40g、人参20g、鹿茸片20g、仙茅20g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)女贞子300g、熟地黄240g、山萸肉200g、黄芪120g、党参120g、巴戟天120g、蛇床子120g、茯苓120g、大枣120g、红花120g、铁皮石斛100g、白芍100g、当归80g、川芎80g、天冬60g、丹参60g、灵芝40g、肉苁蓉40g、甘草40g、人参20g、鹿茸片20g、仙茅20g。将以上22味药合并煎煮3次:第一次加水8倍量,煎煮2小时;第二次加水6倍量,煎煮1.5小时;第三次加水4倍量,煎煮1小时。
(2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.15(80℃热测),后冷却至35℃。将浓缩液加乙醇使含醇量达65%,边加边搅拌使沉淀,在6℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,浓缩液再次加入乙醇使含醇量达85%,边加边搅拌使沉淀,在8℃的温度下静置冷藏48小时,滤过。
(4)回收乙醇至无醇味,减压浓缩至相对密度为1.15的清膏(60℃热测),加纯化水稀释药液体积至1200ml。加入苯甲酸钠2.5g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
实施例12
补气血抗疲劳口服液,具体包括如下组分:黄芪250g、党参180g、女贞子180g、熟地黄150g、山萸肉150g、当归150g、天冬120g、灵芝80g、丹参80g、茯苓80g、大枣80g、红花80g、肉苁蓉80g、巴戟天80g、蛇床子80g、铁皮石斛60g、川芎50g、人参50g、鹿茸片50g、白芍50g、仙茅40g、甘草20g。
上述补气血抗疲劳口服液的制备方法,按如下步骤实施:
(1)黄芪250g、党参180g、女贞子180g、熟地黄150g、山萸肉150g、当归150g、天冬120g、灵芝80g、丹参80g、茯苓80g、大枣80g、红花80g、肉苁蓉80g、巴戟天80g、蛇床子80g、铁皮石斛60g、川芎50g、人参50g、鹿茸片50g、白芍50g、仙茅40g、甘草20g。将以上22味药合并煎煮3次:每次均加水6倍量,第一次煎煮2小时,第二次煎煮1.5小时,第三次煎煮1小时。
(2)将三次提取液合并,滤过,滤液浓缩至相对密度为1.18(75℃热测),后冷却至30℃。将浓缩液加乙醇使含醇量达60%,边加边搅拌使沉淀,在4℃的温度下静置冷藏24小时,滤过。
(3)收取上层清液,回收乙醇至无醇味,浓缩液再次加入乙醇使含醇量达80%,边加边搅拌使沉淀,在6℃的温度下静置冷藏48小时,滤过。
(4)回收乙醇至无醇味,减压浓缩至相对密度为1.18的清膏(60℃热测),加纯化水稀释药液体积至1200ml。加入苯甲酸钠2g,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
动物实验数据:
实验机构:辽宁省肿瘤研究所
实验材料与方法
实验材料:
1.实验动物:Wistar大白鼠,昆明系小白鼠,由中国医科大学动物室提供。
2.实验药物:补气血抗疲劳口服液、乙酰苯肼、硫酸亚铁、细胞培养液。
3.实验仪器:CO2、细胞培养箱。
实验方法:
1.补气血抗疲劳口服液对60CO-γ射线照射小鼠红系祖细胞(CFU-E)的影响
取昆明系小白鼠50只,雌、雄各半,随机分为五组,每组10只,实验组分为本口服液高剂量组0.34ml/kg,中剂量组0.17ml/kg,低剂量组0.08ml/kg,模型对照组,生理盐水空白对照组。除生理盐水组外,其他四组均经60CO-γ射线3.5Gy计量照射,然后灌胃给药,每天一次,连续给药30天,模型对照组与生理盐水组均灌胃给生理盐水。最后一次灌胃给药后24小时,将小白鼠脱臼杀死,用眼科剪刀剪开后肢股骨附近皮肤,分离股骨肌,从股骨头大转子和髌骨处截断取得完整股骨,用消毒纱布包缠,分别除去股骨上附着的肌肉,再用注射器吸取RPML1640培养液冲洗出骨髓细胞,通过4号针头过滤,调整骨髓细胞2×105加入到含有小牛血渍、二巯基乙醇、红细胞刺激因子、RPML1640等组成的培养液中,轻轻摇匀,加盖后先放在倒置显微镜下观察红细胞分散情况,骨髓细胞应分布均匀,不应有聚集成团现象,然后放入CO2培养箱,在37℃,5%CO2浓度培养48小时。培养结果的判定及药物作用。CFU-E集落为8-50个细胞组成的细胞团,凡超过8个细胞的红系细胞集落就为一个灶,每一个灶代表一个红系祖细胞,实验结果见表1
表1:补气血抗疲劳口服液对贫血小鼠(CFU-E)的影响
实验结果表明:补气血抗疲劳口服液对因辐射所致红系祖细胞增殖的降低有明显促进恢复的作用,且随剂量加大而恢复作用明显。
2.补气血抗疲劳口服液对失血性小鼠的补血作用
取昆明系小白鼠40只,雌、雄各半,随机分成四组,每组10只,每鼠眼眶采血0.5ml,同时测定HGB及RBC。失血24小时后,再取血测HGB及RBC,并随即灌胃给本口服液高剂量组0.34ml/kg,中剂量组0.17ml/kg,低剂量组0.08ml/kg,生理盐水对照组。每天灌胃给药一次,连续7天,第8天采血测HGB及RBC,实验结果见表2、表3
表2:补气血抗疲劳口服液对小鼠HGB含量的影响
表3:补气血抗疲劳口服液对小鼠失血性贫血RBC数量的影响
实验结果表明:小白鼠失血0.5ml后,HGB及RBC均明显低于失血前,经灌胃给补气血抗疲劳口服液后,小鼠的HGB及RBC均有所增加,并随剂量加大而作用明显。
3.补气血抗疲劳口服液对乙酰苯肼造成的溶血性小鼠模型的补血作用
取昆明系小白鼠50只,雌、雄各半,体重20±2g,随机分为五组,每组10只,分别灌胃本口服液高剂量组0.34ml/kg,中剂量组0.17ml/kg,低剂量组0.08ml/kg,乙酰苯肼模型组,生理盐水对照组。每天灌胃给药一次,连续10天,后二组灌胃给生理盐水。在第一、五、九天,除生理盐水对照组外,其余四组均皮下注射2%乙酰苯肼,给药剂量分别为0.2、0.1、0.1ml。第11天眼眶取血,用肝素抗凝,取抗凝血20ml于试管中,加Drabkin液5ml(高铁氧化钾200mg,氰化钾50mg,磷酸氢钠1g,限制1000ml)摇匀后在540nm处测OD值,根据标准曲线读取血红蛋白含量,将余下的抗凝血转移至红细胞层积管中,3000转/分离心,读取红细胞压积数,实验结果见表4
表4:补气血抗疲劳口服液对乙酰苯肼造成的溶血性小鼠模型的补血作用
实验结果表明:乙酰苯肼组小白鼠的HGB和红细胞压积均明显低于生理盐水对照组,本口服液组同样给予乙酰苯肼,结果显现,补气血抗疲劳口服液能提高因乙酰苯肼所造成的上述指标的下降,使HGB、红细胞压积均较模型组显著增加。
4.补气血抗疲劳口服液对大鼠缺铁性贫血的影响
取Wistar大白鼠50只,雌、雄各半,体重80±5g刚断奶的大鼠,饲养在不锈钢鼠笼中,喂饲低铁饲料。为加速制成大鼠贫血模型,每隔1天放尾血10滴左右,放尾血时先用75%酒精棉球擦洗鼠尾,再用干棉球擦干,剪去尾尖,自鼠尾根部向尾尖部轻轻抹挤,放血后再用干棉球压迫尾尖部止血。7天取尾血测定HGB和RBC并称大鼠体重,观察动物状态。二周后,其中30只大鼠血红蛋白由2.12±0.31mmol/L下降至1.42±0.13mmol/L,红细胞数由(6.24±0.81)×1012/L,下降至(4.52±0.78)×1012/L,贫血大鼠出现精神萎靡,不爱动等症状,并有皮毛蓬松脱毛现象。将上述30只贫血大鼠分为三组,每组10只,分为本口服液10ml/kg组,生理盐水对照组,硫酸亚铁50mg/kg组,各组继续喂饲低铁饲料,每5天测大鼠的HGB、RBC并于给药前后测大鼠全血铁(用原子吸收分光光度法),经二周后,硫酸亚铁组大鼠HGB回升,贫血恢复正常。实验结果见表5
表5:补气血抗疲劳口服液对大鼠缺铁性贫血治疗和恢复的变化
实验结果表明:补气血抗疲劳口服液对贫血大鼠的Hb及RBC有明显的升高作用,给药后显著高于对照组,与硫酸亚铁组相近。实验结束后,本口服液组大鼠的全血铁含量明显高于给药前,并高于生理盐水对照组,与硫酸亚铁组持平。
实验结论:
补气血抗疲劳口服液对60CO-γ射线造成的小鼠放射性损伤和乙酰苯肼造成的小鼠溶血性贫血,以及对大鼠缺铁性贫血模型均有明显的恢复和治疗作用。
临床试验数据:
【病例1】
1.来诊时间:2013年3月1日。
2.既往病史:患者于2012年8月因吞咽时胸骨后疼痛到某医院就诊,行胃镜检查示:食管中下段肿瘤,病理示食管鳞状细胞癌,后行食管根治术,术后化疗4次,方案为CTX+5-Fu+CBP联合化疗。2013年2月开始出现左侧颈部淋巴结肿大,行诊断性穿刺病理示转移性鳞癌。左颈部可扪及一3cm×3cm淋巴结,质硬,固定不移,有压痛。后因体力虚弱明显(血象:HGB 65g/L,WBC 1.9×109/L,RBC 2.60×1012/L),遂停止化疗,家属寻求中医治疗。
3.治疗:口服本药每日5次,每次1支,连服21日。二诊复查血常规:HGB(血红蛋白)98g/L,WBC(白细胞计数)5.8×109/L,RBC(红细胞计数)3.5×1012/L。血象恢复正常后,患者于2013年3月28日开始行局部淋巴结放射治疗。
2014年2月20日三诊:在某肿瘤医院放疗20次结束,颈部肿块明显缩小,约0.9cm×0.6cm大小。放疗期间坚持服用本药,每日3次,每次1支。中途曾6次复查血常规,各项指标均未下降。
【病例2】
1.既往病史:2014年2月因“发热、刺激性咳嗽3个月”到当地医院诊治,胸部X线片提示右肺癌伴右肺上叶不张,经某医院支气管镜检查,明确诊断为右肺中-高分化腺癌。即行右肺癌切除术。淋巴结转移(3/6),术后患者恢复可。遂予以DDP+NVB联合化疗6周期。患者消化道反应Ⅲ-Ⅳ度,骨髓抑制Ⅲ度,停止化疗。血常规:HGB(血红蛋白)80g/L,WBC(白细胞计数)1.7×109/L,PLT(血小板计数)46×109/L。
2.治疗:口服本药每日4次,每次1支。80支后患者症状逐步好转,血常规:HGB105g/L,WBC 5.1×109/L,PLT 85×109/L,体力基本恢复,为日后第7次化疗奠定基础。
【病例3】
1.既往病史:患者3个月前确诊为胃窦部癌,胃次切除术。术后给予化疗,化疗过程中WBC(白细胞计数)降低为3.5×109/L,HGB(血红蛋白)61g/L,大便隐血试验阳性,故停用化疗。
2.查体:面色苍白,体形略瘦,气短乏力,食后脘腹稍觉胀满,嗳气,间有呕吐,舌质淡,苔薄腻,中部有豆大之剥痕,脉细弱。
3.治疗:累计口服本药100余支,再接受西药化疗。连续进行三个疗程,化疗期间仍坚持服用本药,不良反应轻微,顺利完成治疗。
【病例4】
1.主诉:左侧乳腺癌术后准备化疗。
2.既往病史:患者2015年1月确诊左侧乳腺癌,行手术治疗,病理诊断为浸润性导管癌,腋下淋巴2/6,雌激素受体(+)、孕激素受体(+),Her-B2阴性,准备一周后开始首次化疗。
3.症见:恶心、纳差,睡眠差,易烦躁、出汗,舌淡胖,苔薄白,脉弦细。化疗前辅助检查血常规:WBC(白细胞计数)7.8×109/L,HGB(血红蛋白)110g/L,LYMPHN(淋巴细胞数)2.81×109/L,PLT(血小板计数)145×109/L。
4.治疗:化疗前一周开始口服本药,每日4次,每次1支,连服10日。化疗后第三天检测血常规:WBC 7.2×109/L,HGB 102g/L,LYMPHN 2.52×109/L,PLT 120×109/L。以上各项指标显示均为正常值,未出现骨髓抑制现象。日后坚持配合化疗服用本药,随症加减。经治3年余,症状明显缓解,胃纳、夜寐改善,大便通畅,情绪稳定,血常规及肿瘤标志物多次复查均在正常范围,淋巴结未触及肿大,目前仍在治疗中。
【病例5】
1.既往病史:患原发性肝癌(巨块型)在某肿瘤医院进行动脉插管介入化疗(DDP80mg,5-Fu 1g,MMC 10mg)后2天自感头晕乏力,发热(T:38.5℃),纳减,恶心,呕吐苦清水,痰涎不止,脉象弦细,苔薄黄腻。血检WBC(白细胞计数)从插管化疗前6×109/L,下降至2×109/L,PLT(血小板计数)从80×109/L下降至30×109/L,症属化疗后毒副反应,骨髓抑制严重。
2.治疗:口服本药每日5次,每次1支,同时佐以半枝莲、白花蛇舌草等清热解毒中草药治疗。服药7日后,上述症情明显好转,热度已退,WBC升至3.7×109/L,PLT升至42×109/L。继续服用80支后,自觉症状基本消失,血象复查:WBC升至6.6×109/L,PLT升至85×109/L,已超过化疗前数值。
【病例6】
1.既往病史:贫血病史20多年,曾长期口服硫酸亚铁、复方阿胶浆、维生素B12治疗,疗效不佳,近半年来自觉头晕、乏力逐渐加重,气短懒言,查HGB(血红蛋白)78g/L,遂服红桃K补血治疗,服药2疗程后病情无明显好转。
2.查体:面色苍白无华,唇甲色淡而白,舌淡苔白,脉细。中医辨证属气血两虚。
3.治疗:口服本药每日3次,每次1支。服用60支后患者自觉头晕乏力等症有所好转,察患者面色唇甲已由苍白转红润,复查HGB(血红蛋白)95g/L。嘱患者续服此药3个月,病情明显好转,查HGB已升至123g/L,停药2个月后复查HGB为118g/L。
【病例7】
1.既往病史:西医诊断为白细胞减少症,曾服参芪五味子等中成药效果不佳。
2.查体:面色无华,精神不振,全身乏力,腰酸,失眠多梦,纳呆,怕冷,舌质淡,脉沉迟。查血WBC(白细胞计数)2.7×109/L、HGB(血红蛋白)100g/L。中医辨证为虚劳,治以健脾补肾,滋阴养血。
3.治疗:口服本药每日3次,每次1支。2周后病情明显好转,自觉精神、体力恢复,但有时头晕,仍腰酸,WBC 3.9×109/L。续服1个月后诸症消失,WBC 5.5×109/L。后停药观察,嘱每个月复查1次,连续4次化验血细胞均在正常范围,自觉精神、体质俱佳。
【病例8】
1.既往病史:右肺癌伴右胸膜转移癌、多发性骨髓转移癌,因行化疗及核素治疗后出现严重骨髓抑制,全血细胞均下降,最低时WBC(白细胞计数)3.0×109/L,HGB(血红蛋白)53g/L,PLT(血小板计数)28×109/L,先后输血18次,总量达5400ml。治疗4个月余骨髓抑制仍未修复。
2.治疗:口服本药每日5次,每次1支,连服30日,复查血常规WBC 5.8×109/L,HGB90g/L,PLT 80×109/L;续服45日,每日3次,每次1支,复查血常规WBC 8.1×109/L,HGB119g/L,PLT 129×109/L,骨髓抑制完全恢复。
【病例9】
1.来诊时间:2013年5月15日。
2.主诉:全血细胞减少诊断为慢性再生障碍性贫血6年。
3.既往病史:2012年骨髓检查增生低下,未见有核红细胞,LYMPHP(淋巴细胞比率)68.5%,无巨核细胞,染色体未见异常核型。已用司坦唑醇治疗。
4.症见:乏力,腰酸,纳差,畏寒。查体:舌边齿痕,苔薄白,脉沉。外周血象WBC(白细胞计数)3.0×109/L,HGB(血红蛋白)72g/L,PLT(血小板计数)16×109/L,NEUTP(中性细胞比率)46.1%,LYMPHP(淋巴细胞比率)55.2%。
5.治疗:本例为一慢性再生障碍性贫血的患者,病程已达6年,治疗以坚持口服本药为主,每日5次,每次1支。连续服用9个月外周血象三系明显上升,达缓解:
二诊(2013年6月20日):白细胞计数2.5×109/L,血红蛋白88g/L,血小板计数15×109/L,NEUTP 40%,LYMPHP 53%。症状稍改善,舌脉同前。
三诊(2013年7月22日):白细胞计数2.9×109/L,血红蛋白90g/L,血小板计数17×109/L,NEUTP 38.8%,LYMPHP 45.6%。仍畏寒,肢凉,舌体胖大,脉沉,苔薄白。
四诊(2013年8月25日):白细胞计数3.2×109/L,血红蛋白94g/L,血小板计数21×109/L,治疗同前。
五诊(2013年9月26日):白细胞计数3.65×109/L,血红蛋白98g/L,血小板计数20×109/L,舌边齿痕,苔薄白,脉沉,畏寒好转。
六诊(2013年12月25日):白细胞计数3.42×109/L,血红蛋白108g/L,血小板计数26×109/L,舌边齿痕,苔薄白,脉沉。
七诊(2014年2月27日):白细胞计数3.58×109/L,血红蛋白116g/L,血小板计数43×109/L,舌边齿痕,苔薄白,脉沉。畏寒明显好转,稍有手心发热喜凉。
【病例10】
1.来诊时间:2015年12月7日。
2.主诉:胃癌术后半年,共化疗4次。
3.症见:面色晦暗,自感晨起头晕,纳差,视物模糊,四肢发凉,腰膝酸软,四肢无力,时有肝区疼痛。大便干结,小便尚可,舌淡苔白,脉细弱。查血常规:WBC(白细胞计数)2.1×109/L,RBC(红细胞计数)3.4×1012/L,PLT(血小板计数)68g/L,SGPT(谷丙转氨酶)升高,AFP(甲胎蛋白定量)55.8ng/ml升高。
4.治疗:口服本药每日4次,每次1支。服用100支后,患者诉头晕、乏力好转,面色红润,大便正常。至2016年3月5日二诊时,患者自诉头晕乏力明显缓解,纳可,四肢转温,精神颇佳。复查血常规:WBC升至4.9×109/L,RBC 4.2×1012/L恢复正常,PLT 82g/L,SGPT下降,AFP 38.19ng/mL,偏高于正常值。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (3)
1.一种补气血抗疲劳口服液,其特征在于,以重量份计,包括如下组分:黄芪120~400;熟地黄80~240;白芍50~150;山萸肉80~200;当归80~200;女贞子100~300。
2.根据权利要求1所述的补气血抗疲劳口服液,其特征在于,以重量份计,还含有如下组分:大枣40~120;天冬60~180;党参60~180;灵芝40~120;丹参60~120;甘草20~60;人参20~80;鹿茸片20~80;巴戟天40~120;川芎20~80;红花40~120;铁皮石斛60~150;仙茅20~60;肉苁蓉40~120;蛇床子40~120;茯苓40~120。
3.根据权利要求1所述补气血抗疲劳口服液的制备方法,其特征在于,按如下步骤实施:
(1)将黄芪、熟地黄、白芍、山萸肉、当归及女贞子加水煎煮2~3次,再合并煎液,滤过,滤液浓缩至相对密度为1.10~1.20,75℃~85℃热测,后冷却至30℃~40℃;以重量份计,包括如下组分:黄芪120~400;熟地黄80~240;白芍50~150;山萸肉80~200;当归80~200;女贞子100~300;
(2)将步骤(1)所得产物加乙醇使含醇量达60%~85%,边加边搅拌使沉淀;再静置冷藏,滤过;
(3)收取上层清液,回收乙醇至无醇味,减压浓缩至相对密度为1.10~1.20的清膏;60℃热测;
(4)加纯化水调整药液总量,加入重量百分含量为0.1%~0.25%的苯甲酸钠,充分搅匀使之溶解,静置、滤过、灌封、灭菌即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810593921.1A CN108434239A (zh) | 2018-06-11 | 2018-06-11 | 补气血抗疲劳口服液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810593921.1A CN108434239A (zh) | 2018-06-11 | 2018-06-11 | 补气血抗疲劳口服液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108434239A true CN108434239A (zh) | 2018-08-24 |
Family
ID=63206129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810593921.1A Pending CN108434239A (zh) | 2018-06-11 | 2018-06-11 | 补气血抗疲劳口服液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108434239A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112438953A (zh) * | 2019-09-02 | 2021-03-05 | 邵东县锋正堂生物科技有限公司 | 一种温中散寒纯中药健胃组合片 |
CN114848771A (zh) * | 2021-01-20 | 2022-08-05 | 新疆医联惠康医疗服务有限公司 | 一种提高免疫力的药糖及其制备方法 |
CN115869363A (zh) * | 2022-07-18 | 2023-03-31 | 王世宣 | 一种中草药组合物及其在防治生殖衰老中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829303A (zh) * | 2010-05-11 | 2010-09-15 | 赵双全 | 延年益寿酒 |
CN105194212A (zh) * | 2015-11-09 | 2015-12-30 | 陈慧珊 | 一种调理女性亚健康的中药口服液及制备方法 |
CN105194211A (zh) * | 2015-11-09 | 2015-12-30 | 陈慧珊 | 一种缓解女性慢性疲劳综合征的中药口服液及制备方法 |
CN106266176A (zh) * | 2015-05-11 | 2017-01-04 | 杜乃龙 | 一种治体虚、月经过多的配方 |
-
2018
- 2018-06-11 CN CN201810593921.1A patent/CN108434239A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101829303A (zh) * | 2010-05-11 | 2010-09-15 | 赵双全 | 延年益寿酒 |
CN106266176A (zh) * | 2015-05-11 | 2017-01-04 | 杜乃龙 | 一种治体虚、月经过多的配方 |
CN105194212A (zh) * | 2015-11-09 | 2015-12-30 | 陈慧珊 | 一种调理女性亚健康的中药口服液及制备方法 |
CN105194211A (zh) * | 2015-11-09 | 2015-12-30 | 陈慧珊 | 一种缓解女性慢性疲劳综合征的中药口服液及制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112438953A (zh) * | 2019-09-02 | 2021-03-05 | 邵东县锋正堂生物科技有限公司 | 一种温中散寒纯中药健胃组合片 |
CN114848771A (zh) * | 2021-01-20 | 2022-08-05 | 新疆医联惠康医疗服务有限公司 | 一种提高免疫力的药糖及其制备方法 |
CN115869363A (zh) * | 2022-07-18 | 2023-03-31 | 王世宣 | 一种中草药组合物及其在防治生殖衰老中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN101530597B (zh) | 一种治疗乳房纤维腺瘤和乳腺增生病的药物 | |
CN108434239A (zh) | 补气血抗疲劳口服液及其制备方法 | |
CN102579803B (zh) | 一种治疗化疗后白细胞减少症的药物及其制备方法 | |
CN101843891B (zh) | 一种补血组合物 | |
CN105194225A (zh) | 一种用于治疗小儿缺铁性贫血的中药 | |
CN104524292A (zh) | 一种中药制剂用于制备治疗肥胖药物中的用途 | |
CN104548049A (zh) | 一种治疗老年性骨质疏松症的中药组合物及其制备方法 | |
CN104644956B (zh) | 一种治疗寒凝血瘀型痛经的中药组合物及其制备方法 | |
CN107375714A (zh) | 补肾保健药酒及其制备方法 | |
CN103750304B (zh) | 一种泽泻减肥降脂保健口服液及其制备方法 | |
CN115463173B (zh) | 一种血虚证补血组合物、制备方法及应用 | |
CN104547642A (zh) | 一种治疗女性纤维肌痛综合征的中药组合物 | |
CN104547738A (zh) | 一种治疗肥胖的中药制剂及其制备方法 | |
CN109718305A (zh) | 改善人体气血功能提高耐缺氧延缓衰老的中药组合物 | |
CN109010660A (zh) | 一种提高化疗病人红细胞水平的中药组合物及其制备方法 | |
CN109464589A (zh) | 一种补血汤及其制备方法 | |
CN109758559A (zh) | 一种治疗慢性疲劳综合征的中药组合物及其制备方法和应用 | |
CN107753638B (zh) | 用于促进骨髓造血的药物及其制备方法与用途 | |
CN107898990A (zh) | 一种治疗神经官能症的中药制剂及其制备方法 | |
CN106511881B (zh) | 一种用于补肾安胎的中药组合物及其制备方法 | |
CN106389577A (zh) | 一种使头发黑亮的中药组合物 | |
CN106728869A (zh) | 一种治疗尿毒症合并营养不良的药物及其制作方法 | |
CN119097076A (zh) | 一种基于中医五行心属性特色的药膳组合物及其制备方法和用途 | |
CN105853582A (zh) | 一种含有艾叶的治疗胆石症的药物制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180824 |
|
RJ01 | Rejection of invention patent application after publication |